Table S1.
Changes in laboratory values between baseline and week 16
| Variablesa | Group | Values at time point
|
||
|---|---|---|---|---|
| Baseline | Week 16 | |||
| AST (IU/L) | GCQID | 21.3±0.8 | 20.6±0.9 | |
| Placebo | 22.1±1.1 | 19.5±0.8* | ||
| ALT (IU/L) | GCQID | 20.7±1.5 | 19.7±2.0 | |
| Placebo | 22.0±1.8 | 20.2±1.7 | ||
| ALP (IU/L) | GCQID | 204.9±8.5 | 201.3±8.4 | |
| Placebo | 204.8±8.2 | 208.8±7.6 | ||
| LDH (IU/L) | GCQID | 185.3±3.9 | 190.9±3.8* | |
| Placebo | 184.6±5.4 | 187.1±3.8 | ||
| γ-GTP (IU/L) | GCQID | 30.8±4.3 | 29.1±4.0 | |
| Placebo | 30.1±3.4 | 28.1±3.4 | ||
| T-Bil (mg/dL) | GCQID | 0.75±0.05 | 0.82±0.05* | |
| Placebo | 0.72±0.05 | 0.74±0.06 | ||
| TP (g/dL) | GCQID | 7.33±0.05 | 7.19±0.05* | |
| Placebo | 7.26±0.06 | 7.15±0.05* | ||
| Alb (g/dL) | GCQID | 4.29±0.03 | 4.31±0.03 | |
| Placebo | 4.27±0.04 | 4.29±0.03 | ||
| CPK (IU/L) | GCQID | 124.5±12.6 | 121.3±9.9 | |
| Placebo | 103.0±6.3 | 112.7±7.3 | ||
| Triglyceride (mg/dL) | GCQID | 105.2±8.0 | 97.5±8.4 | |
| Placebo | 109.2±9.0 | 120.0±11.9 | ||
| TC (mg/dL) | GCQID | 220.7±4.7 | 214.3±4.4 | |
| Placebo | 223.3±5.0 | 213.4±5.2** | ||
| HDL-C (mg/dL) | GCQID | 68.7±2.9 | 65.0±2.7** | |
| Placebo | 68.2±2.7 | 62.5±2.3** | ||
| LDL-C (mg/dL) | GCQID | 128.3±3.5 | 126.0±3.7 | |
| Placebo | 130.5±4.5 | 125.1±4.6* | ||
| BUN (mg/dL) | GCQID | 14.0±0.5 | 13.3±0.6* | |
| Placebo | 13.4±0.4 | 13.1±0.4 | ||
| UA (mg/dL) | GCQID | 4.53±0.18 | 4.95±0.19** | |
| Placebo | 4.82±0.16 | 5.13±0.17** | ||
| Cr (mg/dL) | GCQID | 0.69±0.02 | 0.70±0.02 | |
| Placebo | 0.66±0.02 | 0.68±0.02* | ||
| Na (mEq/L) | GCQID | 140.1±0.2 | 139.9±0.2 | |
| Placebo | 140.0±0.2 | 140.5±0.3 | ||
| K (mEq/L) | GCQID | 4.45±0.05 | 4.28±0.05** | |
| Placebo | 4.48±0.05 | 4.26±0.05** | ||
| Cl (mEq/L) | GCQID | 103.2±0.3 | 103.9±0.2* | |
| Placebo | 103.3±0.3 | 104.2±0.3** | ||
| Glucose (mg/dL) | GCQID | 91.3±1.5 | 90.5±1.8 | |
| Placebo | 91.4±1.2 | 91.3±1.4 | ||
| HbA1c (%) | GCQID | 5.00±0.05 | 4.97±0.05 | |
| Placebo | 5.07±0.04 | 5.06±0.04 | ||
| CRP (mg/dL)b | GCQID | 0.10±0.02 | 0.10±0.02 | |
| Placebo | 0.10±0.02 | 0.07±0.01 | ||
| Insulin (μU/mL)b | GCQID | 5.83±0.58 | 5.92±0.69 | |
| Placebo | 5.55±0.65 | 7.23±0.84 | ||
| WBC (×103/μL) | GCQID | 5.74±0.17 | 5.60±0.16 | |
| Placebo | 5.94±0.20 | 5.80±0.19 | ||
| RBC (×104/μL) | GCQID | 463.1±4.3 | 449.0±4.6** | |
| Placebo | 466.1±5.4 | 454.7±5.3** | ||
| Hb (g/dL) | GCQID | 13.9±0.2 | 13.5±0.2** | |
| Placebo | 14.0±0.2 | 13.7±0.2** | ||
| Hct (%) | GCQID | 42.4±0.4 | 41.1±0.4** | |
| Placebo | 42.8±0.5 | 41.5±0.5** | ||
| Plt (×104/μL) | GCQID | 25.1±0.9 | 24.2±0.9* | |
| Placebo | 25.6±0.9 | 24.2±0.8** | ||
Notes: All values are expressed as mean ± standard error for GCQID group (n=48) and placebo group (n=49).
Of the 100 subjects eligible for safety assessment, three (two in the GCQID group and one in the placebo group) dropped out of the study and did not undergo laboratory examinations at week 16.
Values below the detectable limit for CRP and insulin are calculated as 0.05 mg/dL and 2.0 μU/mL, respectively.
P<0.05 and
P<0.01 compared with baseline.
Abbreviations: Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cl, chloride; CPK, creatinine phosphokinase; Cr, creatinine; CRP, C-reactive protein; GCQID, glucosamine hydrochloride, chondroitin sulfate, quercetin glycosides, imidazole peptides, and vitamin D; γ-GTP, gamma-glutamyl transpeptidase; Hb, hemoglobin; HbA1c, hemoglobin A1c; Hct, hematocrit; HDL-C, high-density lipoprotein cholesterol; K, potassium; LDH, lactate dehydrogenase; LDL-C, low-density lipoprotein cholesterol; Na, sodium; Plt, platelet; RBC, red blood cell; T-Bil, total bilirubin; TC, total cholesterol; TP, total protein; UA, uric acid; WBC, white blood cell.